still wait growth
reduc underli forecast ebit due weaker
expect perform reduc target price
maintain outperform rate
organ growth margin continu neg impact cyclic
issu middl east disrupt weather higher raw materi cost
increasingli concern around structur problem busi
remain outperform stock given underli strength
innov pipelin hygiene/corn led manag confid
return good growth
disrupt continu
expect
market
still wait return growth continu forecast return mid-
singl digit structur growth post support hygien
launch corn inocul uptak share gain energy/household
believ commod price support growth
growth new product pipelin believ market gain
comfort improv remaind share
catalysts/risk result risk outperform rate lower oil
valuat new novozym target price dkr
round averag pe multipl ev/ebitda
dcf valuat reduct target price function
valuat metric
number share
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
price apr rate outperform target price analyst mathew hampshire-waugh
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
forecast organ growth repres bottom end
novozym rang forecast underli ebit margin exclud
defer incom payment bioag deal previous chang
increas defer revenue/incom payment bioag busi
dkr previous increas report ebit
revenu reduc forecast revenu led lower growth expect
bioenergi ag feed bioenergi model catch lost volum
weather issu us feed expect continu volum pressur
margin reduc underli margin busi follow
gross margin pressur led higher raw materi lower volum
expect gross margin improv remaind volum
increas raw materi cost abat
ebit adjust reduc underli ebit function reduc revenu
margin
forecast organ sale ebit growth total forecast ebit growth
due follow addit non-organ item
currenc benefit due stronger usd
defer revenu recognit addit earn contribut
defer revenu recognit bioag allianc chang
target price dkk per share averag ev/ebitda multipl price-to-earnings
multipl dcf valuat method shown
price-to-earnings ev/ebitda multipl method use peer givaudan christian
hansem symris sensient
share
equiti
debt
averag spread risk-fre rate
pre-tax cost debt
averag corpor tax rate compani
post-tax cost debt
number year explicit estim
year start termin period
highlight month forward consensu ev/ebitda novozym trade
discount peer discount year histor averag month
forward consensu price-to-earnings novozym trade discount peer
discount year histor averag
rel
compani mention price
